Nurix Therapeutics (NRIX)
(Delayed Data from NSDQ)
$24.47 USD
-0.11 (-0.45%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $24.50 +0.03 (0.12%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
NRIX 24.47 -0.11(-0.45%)
Will NRIX be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for NRIX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NRIX
Nurix Therapeutics, Inc. (NRIX) Reports Q3 Loss, Lags Revenue Estimates
How Much Upside is Left in Nurix Therapeutics (NRIX)? Wall Street Analysts Think 25.27%
NRIX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Are You Looking for a Top Momentum Pick? Why Nurix Therapeutics, Inc. (NRIX) is a Great Choice
Nurix Therapeutics, Inc. (NRIX) Reports Q2 Loss, Lags Revenue Estimates
Beyond Air, Inc. (XAIR) Reports Q4 Loss, Misses Revenue Estimates
Other News for NRIX
Insider Sale: CFO Houte Van Sells Shares of Nurix Therapeutics Inc (NRIX)
Cathie Wood's Ark Innovation, Genomic ETFs Celebrate 10 Years: How Annual Returns Stack Up Against S&P 500
Verizon downgraded, Canadian Pacific upgraded: Wall Street’s top analyst calls
Verizon downgraded, Canadian Pacific upgraded: Wall Street's top analyst calls
Nurix Therapeutics initiated with bullish view at UBS, here's why